Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Performance of Elucirem (Gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) Perfusion of Brain Gliomas Phase IIIb Clinical Trial

NCT06057168 is registered in ClinicalTrials.gov with Guerbet as lead sponsor.

NCT NCT06057168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06057168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Performance of Elucirem (Gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) Perfusion of Brain Gliomas Phase IIIb Clinical Trial
Lead sponsor
Guerbet
Phase
Phase 3
Overall status
Completed
Start date
September 7, 2023
Completion date
November 28, 2024
Enrollment
138 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, primary, brain tumor, recurrent